2020 - Liv Cecilie Vestrheim Thomsen

She was a postdoc in the Gjertsen group from 2017 to 2020, with focus mainly on mass cytometry (CyTOF) analyses, to develop antibody panels for immune cells and checkpoint inhibitor responses in patient-derived materials. She also worked on analyses of data from early phase clinical trials on prostate and ovarian cancer. From June 2020, Liv Cecilie moved on to a Researcher position in the Gjertsen group.

Contact information to Liv Cecilie Vestrheim Thomsen.

Read about Professor Gjertsen's Signaling-Targeted Therapy Group.